Replies to post #70147 on NanoViricides Inc. (NNVC)

[SparkyinIowa]

Excellent information changes iv. Eom

[changes_iv]

If we are going to get cheap shares of NNVC, the time is now. Have management, have money, will travel! The "Nano-Cides Special" has tracks and each will soon be carrying valued cargo, in a controlled race to the market (2014 - 2015).---

[Puffer]

* DengueCide™, our broad-spectrum drug candidate against all four types of dengue, has led to survival of 50% of mice in an ADE (antibody-dependent-enhancement) mouse model of dengue infection, clinically relevant for the high fatality rate dengue DHF/DSS manifestations.

And DengueCide has yet to be optimized. So you can probably count on a significantly higher level of efficacy with an optimized version.

[changes_iv]

I believe was DrFeelgood once made this assertion about polymer nano-particles or micelles,

"...Polymer nano-particles or nanomicelles are used as carriers for the delivery of drug. It has been one of the most attractive areas because of its scientific value and potential of application. The nano-micelles are constructed from very low toxicity substances. They have roughly the same toxicity as water. Drink too much water and it's toxic; the same with NanoViricides materials. NanoViricide micelles are constructed from materials found normally in the metabolic process. So, the nano-micelle is broken down in much the same way. The targeting ligand does not attack human cells or animal cells. It binds to sites on virus cells that the virus uses to bind with human cells..."

A nanoviricide is constructed by chemically attaching virus-binding ligands to a polymeric (water-loving) micelle.

http://online.wsj.com/article/PR-CO-20130422-911033.html

There you have it! This is the answer to "1)pharmacokinetics" from the DengueCide TM -FDA requirements I listed on my previous post. The Cides do end the virus and then its channeled out of the body, with other waste material, through the colon and kidneys.

I still don't know, with any greater degree of certainty, the answer to the remaining two, however:

3)dosing - generally applies to feeding chemicals or medicines in small quantities into a process fluid or to a living being at intervals or to atmosphere at intervals to give sufficient time for the chemical or medicine to react or show the results

*** I could not find info on this; however it may very well be the same dosage as FluCide TM. There are about 100 trillion cells in the human body and about 70 trillion nanomicelles in one dose of FluCide TM. No dose-limiting side effects have been seen for our FluCide TM candidates as yet, indicating that in a severely ill patient, the dosage of FluCide TM can be increased even further.

4)stability - A drug must remain potent and safe long after it leaves a manufacturing facility. Ensuring this safety requires a range of technologies and applications.

*** I could not find info on this; although I am sure it has been answered in the past by companies in the pharmaceutical industry.

DengueCide TM is to be approved by the FDA, likely before Sep 2013 and then it will be on a controlled fast track to the market (2014 - 2015).